Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537373 | 0.90 | ALDH1A1 (0.48) | ALDH1A1CES1CYP1A2CYP2C9MAPT | |
| SCHEMBL16142399 | 0.89 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9MAPTMEN1 | |
| SCHEMBL3676598 | 0.89 | ASAH1 (0.48) | ALDH1A1CES1CYP1A2CYP2C9MAPT | |
| SCHEMBL2040524 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL3678799 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL3679722 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL3678825 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL3678643 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL1537374 | 0.87 | ASAH1 (0.50) | ALDH1A1CES1MEN1KMT2AHPGD | |
| SCHEMBL24169113 | 0.86 | TDP1 (0.58) | ALDH1A1CYP1A2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0576622-B1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK CO (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0576622-A1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1992017821-A1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5141839-A | LITHOGRAPHIC PRINTING PLATES HAVING A RADIATION-SENSITIVE LAYER COMPRISING A PHOTOCROSSLINKABLE POLYMER, A LEUCO DYE, A PHOTOOXIDANT AND A HETEROAROMATIC AMINE N-OXIDE | EASTMAN KODAK COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
| US-5141842-A | Negative working lithography printing plates | EASTMAN KODAK COMPANY (US) | 1992-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | ALDH1A1 1638/4885CES1 628/4885CYP1A2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.